Revenue responsibility for $1 million to $230 million enterprises. Kranzler became Chief Executive Officer of Cypress Bioscience (formerly IMRE Corporation) where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia, and Karuna Pharmaceuticals, focusing on the treatment of Schizophrenia.Īccomplished Senior Executive with 20+ years of diverse healthcare market experience across the continuum of care: physician office, hospital, outpatient, integrated delivery networks (IDN), group purchasing (GPO), payer organizations, medical banking, retail and consumer directed healthcare.ĭemonstrated success in shaping corporate direction, designing and executing business strategies, building and leading sales and cross functional teams to deliver profitable results in a variety of corporate environments including: startup, rapid growth, turn-around, strategic repositioning and Fortune 100.
He took Cytel public, and negotiated partnerships with both global and Japanese pharmaceutical companies that set new standards for deal size and structure. In 1989, he became the Chief Executive Officer of Cytel Corporation, a company focused on the development of immunomodulatory drugs. Kranzler joined McKinsey & Company where he contributed toward founding the Firm’s pharmaceutical practice.
He is currently acting as Founder and Chief Executive Officer of Perception Neuroscience, Acting Chief Medical Officer of Pastorus, Board Member of Pastorus, Avenue Pharmaceuticals, and ImmunoBrain Checkpoint, and Advisor to small and large companies in the pharma/ biotech space.Īfter graduating from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology, Dr. Jay Kranzler has been a Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years.
0 kommentar(er)
